Systemic steroid pretreatment without presteroid WBC documentation
Known intolerance to steroid therapy
Current systemic steroid therapy other than physiologic replacement (i.e. prednisone ? 10 mg or equivalent). Inhaled or topical steroid use is allowed.
Patients who are planned to receive concurrent growth factor, systemic steroid or other immunosuppressive therapy or cytotoxic agent
Patients receiving systemic steroid therapy or any other systemic immunosuppressive medication. Local steroid therapies are acceptable
Systemic steroid therapy or any immunosuppressive therapy
Systemic steroid or other immunosuppressive therapy within 4 weeks of starting the study
Receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy =< 7 days prior to registration; EXCEPTIONS:\r\n* Low doses of steroids (=< 20 mg of prednisone or equivalent dose of other steroid/day)\r\n* Previous use of corticosteroids is allowed\r\n* After initiation of MK-3475 therapy, steroid can be used for management of potential immune mediated adverse events (AE) for less than 8 weeks of therapy\r\n* Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are permitted
Concurrent systemic steroid therapy
Concurrent systemic steroid therapy
Concurrent systemic steroid therapy; (NOTE: Patients with recurrent glioblastoma who require steroids for clinical indications are eligible)
Concurrent systemic steroid therapy.
Known intolerance to the required dose and schedule of steroid therapy as determined by the investigator
Evidence of clinically significant immunosuppression such as the following:\r\n* Primary immunodeficiency state such as severe combined immunodeficiency disease\r\n* Concurrent opportunistic infection\r\n* Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 7 days prior to enrollment; however, in the setting of non-immune mediated indications for steroid use, chronic/active low dose steroid use may be permitted at the discretion of the principal investigator; the dose of steroid allowed in this setting is also at the discretion of the principal investigator; (use of inhaled or topical steroids is permitted)
Systemic steroid therapy required, except for patients with glioblastoma (cohort 4)
Concurrent systemic steroid therapy
No systemic steroid or steroid eye drop use within 2 weeks prior to initiation of experimental therapy; limited doses of systemic steroids to prevent IV contrast, allergic reaction or anaphylaxis (in patients who have known contrast allergies) are allowed
Has received more than one systemic treatment for steroid refractory aGvHD.
Concurrent systemic steroid therapy
Concurrent systemic steroid therapy
Systemic steroid therapy
Systemic steroid therapy unless for physiologic replacement
Concurrent systemic steroid therapy
Concurrent systemic steroid therapy
Have received systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses) within one week prior to first dose; Note: systemic steroid therapy is allowed for subjects on replacement therapy as long as prednisone =< 10 mg or its steroid equivalent, and those patients should continue at the same dose through the trial
Systemic steroid therapy or immunosuppressive therapy within 14 days before vaccine administration
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Systemic steroid or immunosuppressive therapy within 14 days before vaccine administration
Concurrent systemic steroid therapy
Concurrent systemic steroid therapy
Concurrent systemic steroid therapy
Require steroid therapy or steroid-containing compounds, or have used systemic steroids in the past 4 weeks, or have used topical or inhalational steroids in the past 2 weeks prior to lymphodepletion; the exception being patients on chronic physiologic dose of steroid (Turnstile II)
Systemic or topical steroid use or other immunosuppressive therapy within the past 14 days
Systemic steroid therapy within 28 days before vaccine administration
Anticipated need for systemic steroid therapy within 28 days after vaccine administration
Require steroid therapy or steroid-containing compounds, or have used systemic steroids in the past 30 days, or have used topical or inhalational steroids in the past 2 weeks prior to lymphodepletion; Exception: patients on physiologic dose of steroid (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)
History of organ transplant requiring immunosuppression; or history of pneumonitis or interstitial lung disease requiring treatment with systemic steroids; or a history of receiving systemic steroid therapy or any other immunosuppressive medication ? 3 days prior to study initiation. Daily steroid replacement therapy (eg, prednisone or hydrocortisone) and corticosteroid use to manage AEs are permitted.
Concurrent systemic steroid therapy
Patients who received most recent therapy =< 4 weeks prior to registration; NOTE: use of systemic steroid therapy is allowed pretreatment
Concurrent systemic steroid therapy
Known intolerance to steroid therapy
Concurrent systemic steroid therapy
Patients requiring concurrent systemic steroid therapy higher than physiologic dose (7.5 mg/day of prednisone).
Patients receiving systemic treatment with systemic steroid therapy or any other immunosuppressive medication at any dose level that would interfere with the action of the study drugs in the opinion of the investigator
Chronic use of steroid therapy.
Known intolerance to steroid therapy
Steroid dose increased in the most recent two weeks
Known intolerance to steroid therapy
No systemic steroid or steroid eye drop use within 2 weeks prior to initiation of experimental therapy; limited doses of systemic steroids to prevent intravenous (IV) contrast, allergic reaction or anaphylaxis (in patients who have known contrast allergies) are allowed
Known intolerance to steroid therapy
Patients who are immunocompromised as listed as follows:\r\n* Human immunodeficiency virus positivity\r\n* Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids (including steroid eye drops) or other immune suppressive drugs, within 28 days before the first planned dose of PSA-TRICOM; nasal, or inhaled steroid, and topical steroid creams for small body areas are not excluded\r\n* Patients who have undergone allogeneic peripheral stem cell transplantation, or solid organ transplantation requiring immunosuppression \r\n* History of splenectomy
Concurrent systemic steroid therapy
Concurrent systemic or inhaled steroid therapy
Concurrent systemic steroid therapy
Concurrent systemic steroid therapy
Concurrent systemic steroid therapy
Current use of systemic steroid medication
Concurrent systemic steroid therapy
Concurrent systemic steroid therapy
Systemic steroid or other immunosuppressive therapy within 4 weeks of starting the study
Concurrent systemic steroid therapy
Systemic steroid therapy requirement
Their neurological function is stable for at least 30 days and either off steroid therapy or on a stable steroid regimen.
Concurrent systemic steroid therapy higher than physiologic dose (> 7.5 mg/day of prednisone)
Concurrent systemic steroid therapy
Concurrent systemic steroid therapy
History of steroid psychosis
Caregivers : No steroid medications
Known intolerance of topical steroid preparations
Patient on steroid therapy
Chronic steroid use
Any oral steroid use within 2 weeks of testing
Known intolerance to steroid therapy
Patients may not have a need for chronic systemic steroid therapy
